Indegene Ltd

Fri 31/07/2026,15:59:45 | NSE : INDGN

₹515.150.45 (0.09%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 510.35

Previous Close

₹ 514.70

Volume

1142293

Mkt Cap ( ₹ Cr)

₹ 12410.03

High

₹ 536.50

Low

₹ 500.35

52 Week High

₹ 596.80

52 Week Low

₹ 414.00

Book Value Per Share

₹ 130.29

Dividend Yield

0.00

Face Value

₹ 2.00

What's Your Call?

Collective community sentiment on Indegene Ltd

Your Vote -

Buy

80.00%

Hold

0.00%

Sell

20.00%

80.00%

5 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

0%

Sell Order Quantity

100%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

515.15

23

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

23

Option Chain

Analyzes market sentiment, predicts Indegene Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Indegene - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    31 Jul 2026, 12:30PM Audio Recording of the Q1 FY27 Earnings Call
  • Indegene - Investor Presentation

    30 Jul 2026, 7:38PM Indegene Limited has informed the Exchange about Investor Presentation
  • Indegene - Announcement under Regulation 30 (LODR)-Investor Presentation

    30 Jul 2026, 7:35PM Analyst Presentation and fact sheet - financial results for the quarter ended June 30, 2026
  • Indegene - Press Release

    30 Jul 2026, 7:33PM Indegene Limited has informed the Exchange regarding a press release dated July 30, 2026, titled ""Indegene Delivers Strong Q1 FY27 Performance, Reven
  • Indegene - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    30 Jul 2026, 7:26PM Press Release
  • Indegene - Monitoring Agency Report

    30 Jul 2026, 7:23PM Monitoring Agency Report
  • Indegene - Announcement under Regulation 30 (LODR)-Monitoring Agency Report

    30 Jul 2026, 7:21PM Monitoring Agency Report
  • Indegene - Allotment of Securities

    30 Jul 2026, 7:04PM Indegene Limited has informed the Exchange regarding allotment of 12451 securities pursuant to ESOP/ESPS at its meeting held on July 30, 2026
  • Indegene - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    30 Jul 2026, 7:02PM Allotment of Shares under ESOP Scheme 2020
  • Indegene - Unaudited Financial Results For The Quarter Ended June 30, 2026

    30 Jul 2026, 6:57PM Unaudited Financial Results for the Quarter ended June 30, 2026
  • Indegene - Outcome of Board Meeting

    30 Jul 2026, 6:51PM Indegene Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
  • Indegene - Board Meeting Outcome for For The Meeting Of Board Of Directors Held On 30Th July, 2026

    30 Jul 2026, 6:46PM Outcome of the Board Meeting held on 30th July, 2026
  • Indegene - Copy of Newspaper Publication

    18 Jul 2026, 3:24PM Indegene Limited has informed the Exchange about Copy of Newspaper Publication
  • Indegene - Letter To Shareholders In Relation To Annual Report Of The Company For The Financial Year 2025-26

    17 Jul 2026, 7:08PM Letter to Shareholders in relation to Annual Report of the Company for the financial year 2025-26
  • Indegene - General Updates

    17 Jul 2026, 7:04PM Indegene Limited has informed the Exchange about Letter to Shareholders in relation to Annual Report of the Company for the financial year 2025-26
  • Indegene has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2026

    17 Jul 2026, 6:10PM As of June 2026, 100.00% owned by Public. <p align=justify> Institutional holds 18.66% (Insurance Companies 0.02%) and Non-Institutional holds 81.34%
  • Indegene - General Updates

    17 Jul 2026, 1:03PM Indegene Limited has informed the Exchange about Business Responsibility and Sustainability Report for the financial year 2025-26
  • Indegene - Shareholders meeting

    17 Jul 2026, 12:52PM Indegene Limited has informed the Exchange about Shareholders meeting
  • Indegene - Business Responsibility and Sustainability Reporting (BRSR)

    17 Jul 2026, 12:46PM Business Responsibility and Sustainability Report for the financial year 2025-26
  • Indegene - Reg. 34 (1) Annual Report.

    17 Jul 2026, 12:41PM Annual Report of the Company for financial year 2025-26
  • Indegene - Notice Of The 28Th Annual General Meeting Of The Company

    17 Jul 2026, 12:30PM Notice of the 28th Annual General Meeting of the Company
  • Indegene - Copy of Newspaper Publication

    16 Jul 2026, 11:47AM Indegene Limited has informed the Exchange about Copy of Newspaper Publication
  • Indegene has declared 112.50% Final dividend for the financial year March 2026

    16 Jul 2026, 9:50AM Indegene Ltd. on Wednesday, 29 April 2026, has announced Final dividend of 112.50 percent on Equity Share, to its shareholders holding shares on the r
  • Indegene - Record Date

    15 Jul 2026, 6:58PM Indegene Limited has informed the Exchange that Record date for the purpose of Dividend is 31-Jul-2026.
  • Indegene - Record Date For Payment Of Final Dividend

    15 Jul 2026, 6:56PM Record date for payment of Final Dividend
  • Indegene - Outcome of Board Meeting

    15 Jul 2026, 6:54PM Indegene Limited has informed the Exchange regarding Outcome of Board Meeting held on July 15, 2026.
  • Indegene - Board Meeting Outcome for Outcome Of Board Meeting

    15 Jul 2026, 6:51PM Outcome of the Board Meeting held on July 15, 2026
  • Indegene - Analysts/Institutional Investor Meet/Con. Call Updates

    10 Jul 2026, 3:17PM Indegene Limited has informed the Exchange about Schedule of meet
  • Indegene - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    10 Jul 2026, 3:12PM Intimation of Indegene Limited Q1 FY27 Earnings Call
  • Indegene - Board Meeting Intimation for Consideration Of The Unaudited Standalone And Consolidated Financial Results For The

    10 Jul 2026, 2:49PM Indegene Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/07/2026 ,inter alia, to consider and approve
  • Indegene - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    10 Jul 2026, 2:36PM Indegene Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
  • Indegene - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    10 Jul 2026, 2:34PM Certificate under Regulation 74(5) of SEBI DP Regulations, 2018
  • Indegene - Trading Window

    25 Jun 2026, 3:21PM Indegene Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
  • Indegene - Disclosure under SEBI Takeover Regulations

    12 Jun 2026, 11:37AM Indegene Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial
  • Indegene - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    11 Jun 2026, 5:14PM Intimation of Investors / Analysts Meeting
  • Indegene - Analysts/Institutional Investor Meet/Con. Call Updates

    11 Jun 2026, 5:02PM Indegene Limited has informed the Exchange about Schedule of meet
  • Indegene - Analysts/Institutional Investor Meet/Con. Call Updates

    3 Jun 2026, 3:17PM Indegene Limited has informed the Exchange about Schedule of meet
  • Indegene - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    3 Jun 2026, 3:39PM Intimation of Investor Meeting
  • Indegene - Announcement under Regulation 30 (LODR)-Investor Presentation

    28 May 2026, 1:52PM Revised Investor Presentation
  • Indegene - Analysts/Institutional Investor Meet/Con. Call Updates

    28 May 2026, 1:52PM Indegene Limited has informed the Exchange about Presentation
  • Indegene - Announcement under Regulation 30 (LODR)-Investor Presentation

    27 May 2026, 8:21PM Investor Presentation
  • Indegene - Analysts/Institutional Investor Meet/Con. Call Updates

    27 May 2026, 8:08PM Indegene Limited has informed the Exchange about Investor Presentation
  • Indegene - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    20 May 2026, 7:34PM Intimation of Investors / Analysts Meeting
  • Indegene - Analysts/Institutional Investor Meet/Con. Call Updates

    20 May 2026, 7:34PM Indegene Limited has informed the Exchange about Schedule of meet
  • Indegene - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    6 May 2026, 7:19PM Transcript of earnings conference call on financial results for the quarter and year ended March 31, 2026
  • Indegene - Analysts/Institutional Investor Meet/Con. Call Updates

    6 May 2026, 7:15PM Indegene Limited has informed the Exchange about Transcript
  • Indegene - Action(s) initiated or orders passed

    5 May 2026, 10:27PM Indegene Limited has informed the Exchange about Action(s) initiated or orders passed
  • Indegene - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    4 May 2026, 5:59PM Press Release
  • Indegene - Press Release

    4 May 2026, 5:58PM Indegene Limited has informed the Exchange regarding a press release dated May 04, 2026, titled ""Indegene Identified as a Leader in ISG Provider Lens
  • Indegene - Copy of Newspaper Publication

    1 May 2026, 5:44PM Indegene Limited has informed the Exchange about Copy of Newspaper Publication
  • Indegene Ltd

    9 Oct 2025 , 9:01AM Indegene : The company is ramping up its US strategy, betting that pricing pressures under the Trump administration will accelerate the pharmaceutical industry’s shift toward digital-first, non-personal marketing. The company’s recent $104 million acquisition of BioPharm Communications, a Pennsylvania-based adtech firm, is central to this pivot. BioPharm acquisition from Omnicom Group gives Indegene access to a proprietary database of more than 15 million physician engagements and around 300 million exposure events, enabling hyper-targeted campaigns for top pharma clients.
  • Indegene Ltd

    4 Jun 2025 , 9:49AM Indegene: Carlyle Group is set to exit a 10.2% stake in the company for at least Rs 1,420 crore. The floor price is Rs 580 per share, which is a 6% discount from the current market price.
  • Indegene

    20 Mar 2025 , 11:34AM The company launched a new centre In London to expand in Europe. This aligns with the company's long-term growth strategy in Europe, reiterating its commitment to enable life sciences clients in the region to be future-ready.
  • Indegene

    3 Dec 2024 , 11:16AM Global private equity firm Carlyle-backed CA Dawn Investments likely to divest 2.9% stake in Indegene via block deal at Rs.615 per share. As per media sources, the sale could raise approximately Rs 470 crore, based on the offered floor price.
  • Indegene announces strategic collaboration with Microsoft

    11 Jul 2024 , 11:38AM Indegene collaborates with Microsoft to help life sciences companies scale up Generative AI adoption

Key fundamentals

Evaluate the intrinsic value of Indegene Ltd stock 

Name March-26 March-25 March-24 March-23 March-22
Assets 2080.5 1888.2 953.8 795.3 650
Liabilities 2080.5 1888.2 953.8 795.3 650
Equity 48.1 47.9 44.4 44.3 0.4
Gross Profit 248.1 180.5 168 177.9 168.7
Net Profit 211.9 181.3 137.9 130.2 132.7
Cash From Operating Activities 345.6 129 176.2 81.9 38.2
NPM(%) 17.36 16.57 13.18 12.94 15.85
Revenue 1220.6 1093.6 1045.6 1005.7 836.7
Expenses 972.5 913.1 877.6 827.8 668
ROE(%) 6.75 5.77 4.39 4.14 4.22

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
31 Jul 2026 2.25 112.5 0 495.45
13 Jun 2025 2 100 0 571.5

Peers

Other companies within the same industry or sector that are comparable to Indegene Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Visagar Polytex Ltd 0.52 1.96 0.00 15071.17 -5.25 0.00
India Motor Parts and Accessories Ltd 1084.40 -0.14 13.83 642.60 773.64 3.04
Madhya Pradesh Today Media Ltd 46.00 0.00 7.07 235.21 65.12 0.00
Hathway Cable and Datacom Ltd 10.77 0.19 25.64 91142.45 23.25 0.00

Company Info

Our Company was incorporated as `Indegene Lifesystems Private Limited' at Ahmedabad, Gujarat, as a private limited company, under the Companies Act, 1956, pursuant to a certificate of incorporation dated October 16, 1998, issued by the Registrar of Companies, Gujarat, Dadra & Nagar Haveli at Ahmedabad. Thereafter, the registered office of our Company was shifted from Gujarat to Karnataka in June 2003, and then, from Karnataka to Maharashtra in May 2014. Further, pursuant to a resolution passed by our Shareholders at the EGM held on February 29, 2016, the name of our Company was changed to `Indegene Private Limited' and a fresh certificate of incorporation was issued by the Registrar of Companies, Maharashtra at Mumbai on May 26, 2016. The name of our Company was changed to better reflect the nature of business undertaken by our Company. Thereafter, the registered office of our Company was shifted from Maharashtra to Karnataka in February 2017. Subsequently, our Company was converted from a private limited company to a public limited company, pursuant to a special resolution passed by our Shareholders at the EGM held on November 7, 2022 and the name of our Company was changed to `Indegene Limited' and a fresh certificate of incorporation was issued to our Company by the RoC, on November 17, 2022.Major events and milestones:2005-Raised funding from Nadathur Holdings & Investments Private Limited-Expanded operations to the USA by incorporating a subsidiary named Indegene, Inc.-Expanded operations to Southeast Asia by incorporating a subsidiary named Indegene Fareast Pte. Ltd. in Singapore2006-Acquisition of Medsn, Inc.1 a company in the USA which is engaged in medical education and marketing business, by one of our Material Subsidiaries, Indegene, Inc.2 through the merger of Medsn Merger Sub, Inc., an erstwhile wholly owned subsidiary of Indegene, Inc. with Medsn, Inc.2007-Expanded our services to include European territory2008-Received BS ISO/IEC 27001:2005 certification for information security management system32009-Received ISO 9001:2000 certification for quality management system42012-Expanded operations to China by incorporating a subsidiary named Indegene Lifesystems Consulting (Shanghai) Co., Ltd.2017-Acquisition of the Encima Group, Inc., a corporation which operates a digital service, marketing automation and analytics services business supporting clients in healthcare, life sciences and other industries by one of our Material Subsidiaries, ILSL Holdings, Inc.2020-Acquisition of DT Associates Research and Consulting Services Limited, a consulting services company in UK supporting clients in healthcare, life sciences and other industries by one of our Material Subsidiaries, ILSL Holdings, Inc.-Launched Indegene Digital Summit, a symposium on digital transformation and customer experience in life sciences2021-Expanded operations to Japan by incorporating a subsidiary named Indegene Japan, LLC-Raised equity funding from CA Dawn Investments and Brighton Park Capital-Received BS ISO/IEC 27701:2019 certification for privacy information management system52022-Acquisition of Medical Marketing Economics, LLC by one of our Material Subsidiaries, ILSL Holdings, Inc. and subsequent merger of Medical Marketing Economics, LLC with Indegene, Inc.-Expanded global operations with new offices in Mexico2023-Acquisition of Cult Health, a company engaged in the business of providing advertising services to parties in the healthcare sector, by one of our Material Subsidiaries, ILSL Holdings, Inc.-Expanded our presence in Europe with the acquisition of Indegene Healthcare Germany GmbH (formerly Sotus 852 GmbH) by our subsidiary, Indegene Ireland Limited-Launched Invisage, an AI-enabled hybrid omnichannel sales and marketing platform2024-Acquisition of Trilogy Writing & Consulting GmbH, a company engaged in providing high-end medical writing to customers that include market-leading pharmaceutical companies, along with three of its wholly owned subsidiaries, by one of our Subsidiaries, Indegene Ireland Limited.-Ranked 167 in The Next 500 India's Largest Emerging Companies by Fortune India.2025-Deloitte Names Indegene a Winner of Enterprise Growth Awards 2025.-"Indegene Wins BIG Innovation Award_January 2025."-Indegene Acquired BioPharm to Expand AI-Driven Marketing and AdTech for Global Pharma.-Everest Group Recognized Indegene as a Leader in Life Sciences AI and Analytics for Commercial PEAK Matrix Assessment 2025.-Indegene Launched NEXT Medical Writing Automation to Streamline Complex Medical Writing Workflows with GenAI.-Indegene Launched Cortex, A Fit-For-Purpose Generative AI Platform, Verticalized For The Life Sciences Industry.

Our Company was incorporated as `Indegene Lifesystems Private Limited' at Ahmedabad, Gujarat, as a private limited company, under the Companies Act, 1956, pursuant to a certificate of incorporation dated October 16, 1998, issued by the Registrar of Companies, Gujarat, Dadra & Nagar Haveli at Ahmedabad. Thereafter, the registered office of our Company was shifted from Gujarat to Karnataka in June 2003, and then, from Karnataka to Maharashtra in May 2014. Further, pursuant to a resolution passed by our Shareholders at the EGM held on February 29, 2016, the name of our Company was changed to `Indegene Private Limited' and a fresh certificate of incorporation was issued by the Registrar of Companies, Maharashtra at Mumbai on May 26, 2016. The name of our Company was changed to better reflect the nature of business undertaken by our Company. Thereafter, the registered office of our Company was shifted from Maharashtra to Karnataka in February 2017. Subsequently, our Company was converted from a private limited company to a public limited company, pursuant to a special resolution passed by our Shareholders at the EGM held on November 7, 2022 and the name of our Company was changed to `Indegene Limited' and a fresh certificate of incorporation was issued to our Company by the RoC, on November 17, 2022.Major events and milestones:2005-Raised funding from Nadathur Holdings & Investments Private Limited-Expanded operations to the USA by incorporating a subsidiary named Indegene, Inc.-Expanded operations to Southeast Asia by incorporating a subsidiary named Indegene Fareast Pte. Ltd. in Singapore2006-Acquisition of Medsn, Inc.1 a company in the USA which is engaged in medical education and marketing business, by one of our Material Subsidiaries, Indegene, Inc.2 through the merger of Medsn Merger Sub, Inc., an erstwhile wholly owned subsidiary of Indegene, Inc. with Medsn, Inc.2007-Expanded our services to include European territory2008-Received BS ISO/IEC 27001:2005 certification for information security management system32009-Received ISO 9001:2000 certification for quality management system42012-Expanded operations to China by incorporating a subsidiary named Indegene Lifesystems Consulting (Shanghai) Co., Ltd.2017-Acquisition of the Encima Group, Inc., a corporation which operates a digital service, marketing automation and analytics services business supporting clients in healthcare, life sciences and other industries by one of our Material Subsidiaries, ILSL Holdings, Inc.2020-Acquisition of DT Associates Research and Consulting Services Limited, a consulting services company in UK supporting clients in healthcare, life sciences and other industries by one of our Material Subsidiaries, ILSL Holdings, Inc.-Launched Indegene Digital Summit, a symposium on digital transformation and customer experience in life sciences2021-Expanded operations to Japan by incorporating a subsidiary named Indegene Japan, LLC-Raised equity funding from CA Dawn Investments and Brighton Park Capital-Received BS ISO/IEC 27701:2019 certification for privacy information management system52022-Acquisition of Medical Marketing Economics, LLC by one of our Material Subsidiaries, ILSL Holdings, Inc. and subsequent merger of Medical Marketing Economics, LLC with Indegene, Inc.-Expanded global operations with new offices in Mexico2023-Acquisition of Cult Health, a company engaged in the business of providing advertising services to parties in the healthcare sector, by one of our Material Subsidiaries, ILSL Holdings, Inc.-Expanded our presence in Europe with the acquisition of Indegene Healthcare Germany GmbH (formerly Sotus 852 GmbH) by our subsidiary, Indegene Ireland Limited-Launched Invisage, an AI-enabled hybrid omnichannel sales and marketing platform2024-Acquisition of Trilogy Writing & Consulting GmbH, a company engaged in providing high-end medical writing to customers that include market-leading pharmaceutical companies, along with three of its wholly owned subsidiaries, by one of our Subsidiaries, Indegene Ireland Limited.-Ranked 167 in The Next 500 India's Largest Emerging Companies by Fortune India.2025-Deloitte Names Indegene a Winner of Enterprise Growth Awards 2025.-"Indegene Wins BIG Innovation Award_January 2025."-Indegene Acquired BioPharm to Expand AI-Driven Marketing and AdTech for Global Pharma.-Everest Group Recognized Indegene as a Leader in Life Sciences AI and Analytics for Commercial PEAK Matrix Assessment 2025.-Indegene Launched NEXT Medical Writing Automation to Streamline Complex Medical Writing Workflows with GenAI.-Indegene Launched Cortex, A Fit-For-Purpose Generative AI Platform, Verticalized For The Life Sciences Industry.

Parent Organisation

Indegene Ltd.

Founded

16/10/1998

Managing Director

Mr.Manish Gupta

NSE Symbol

INDGNEQ

FAQ